Myriad Genetics, Inc.

NasdaqGS:MYGN Stock Report

Market Cap: US$914.0m

Myriad Genetics Valuation

Is MYGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MYGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$36.34
Fair Value
72.5% undervalued intrinsic discount
17
Number of Analysts

Below Fair Value: MYGN ($10.01) is trading below our estimate of fair value ($36.34)

Significantly Below Fair Value: MYGN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MYGN?

Key metric: As MYGN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MYGN. This is calculated by dividing MYGN's market cap by their current revenue.
What is MYGN's PS Ratio?
PS Ratio1.1x
SalesUS$837.60m
Market CapUS$914.00m

Price to Sales Ratio vs Peers

How does MYGN's PS Ratio compare to its peers?

The above table shows the PS ratio for MYGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.9x
NTLA Intellia Therapeutics
16.1x57.0%US$931.7m
GYRE Gyre Therapeutics
8.6xn/aUS$909.0m
ZYME Zymeworks
11.6x18.7%US$885.0m
CDNA CareDx
3.2x12.3%US$1.1b
MYGN Myriad Genetics
1.1x6.0%US$914.0m

Price-To-Sales vs Peers: MYGN is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (9.9x).

Price to Sales Ratio vs Industry

How does MYGN's PS Ratio compare vs other companies in the US Biotechs Industry?

142 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.9.7x20.3%
MYGN Myriad Genetics
 1.1x6.0%US$914.00m
BIIB Biogen
2.1x-0.1%US$20.62b
MRNA Moderna
3.9x16.7%US$12.63b
MYGN 1.1xIndustry Avg. 9.7xNo. of Companies142PS01632486480+
142 CompaniesEstimated GrowthMarket Cap
Industry Avg.9.7x27.2%
MYGN Myriad Genetics
 1.1x61.6%US$914.00m
No more companies

Price-To-Sales vs Industry: MYGN is good value based on its Price-To-Sales Ratio (1.1x) compared to the US Biotechs industry average (9.7x).

Price to Sales Ratio vs Fair Ratio

What is MYGN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MYGN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.1x
Fair PS Ratio2.9x

Price-To-Sales vs Fair Ratio: MYGN is good value based on its Price-To-Sales Ratio (1.1x) compared to the estimated Fair Price-To-Sales Ratio (2.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MYGN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$10.01
US$18.01
+79.9%
31.6%US$29.00US$11.00n/a17
Mar ’26US$10.73
US$19.41
+80.9%
30.0%US$29.00US$11.00n/a16
Feb ’26US$12.67
US$19.54
+54.2%
27.0%US$29.00US$13.00n/a16
Jan ’26US$13.71
US$22.60
+64.8%
26.7%US$35.00US$13.00n/a16
Dec ’25US$16.27
US$23.77
+46.1%
24.9%US$35.00US$15.00n/a15
Nov ’25US$17.99
US$29.71
+65.1%
21.5%US$40.00US$18.00n/a15
Oct ’25US$27.03
US$29.37
+8.7%
20.3%US$40.00US$18.00n/a15
Sep ’25US$28.33
US$29.19
+3.0%
21.0%US$40.00US$18.00n/a14
Aug ’25US$27.60
US$25.85
-6.4%
19.7%US$35.00US$17.00n/a13
Jul ’25US$23.97
US$25.23
+5.3%
20.2%US$35.00US$17.00n/a13
Jun ’25US$22.76
US$25.33
+11.3%
19.6%US$35.00US$17.00n/a12
May ’25US$19.47
US$24.08
+23.7%
16.1%US$31.00US$17.00n/a12
Apr ’25US$21.44
US$24.50
+14.3%
14.4%US$31.00US$17.00n/a12
Mar ’25US$22.18
US$24.50
+10.5%
14.4%US$31.00US$17.00US$10.7312
Feb ’25US$21.61
US$22.50
+4.1%
18.6%US$31.00US$14.00US$12.6712
Jan ’25US$19.14
US$21.85
+14.1%
19.0%US$28.00US$14.00US$13.7113
Dec ’24US$19.23
US$21.11
+9.8%
20.9%US$28.00US$14.00US$16.279
Nov ’24US$15.74
US$21.33
+35.5%
16.4%US$27.00US$17.00US$17.999
Oct ’24US$16.04
US$22.33
+39.2%
13.8%US$27.00US$17.00US$27.039
Sep ’24US$18.02
US$22.33
+23.9%
13.8%US$27.00US$17.00US$28.339
Aug ’24US$21.77
US$23.61
+8.5%
16.6%US$30.00US$18.00US$27.609
Jul ’24US$23.18
US$22.94
-1.0%
16.2%US$30.00US$18.00US$23.979
Jun ’24US$23.10
US$22.94
-0.7%
16.2%US$30.00US$18.00US$22.769
May ’24US$21.70
US$22.28
+2.7%
17.8%US$30.00US$18.00US$19.479
Apr ’24US$23.23
US$21.39
-7.9%
14.0%US$27.00US$18.00US$21.449
Mar ’24US$21.42
US$20.81
-2.8%
12.4%US$25.00US$18.00US$22.188
Analyst Price Target
Consensus Narrative from 17 Analysts
US$18.01
Fair Value
44.4% undervalued intrinsic discount
17
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 15:41
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Myriad Genetics, Inc. is covered by 41 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack MeehanBarclays
Derek TallerBenchmark Company
Michael RyskinBofA Global Research